A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/51 (2006.01) A61K 31/436 (2006.01) A61K 47/42 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2680207
The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
La présente invention concerne des procédés de traitement, de stabilisation, de prévention du cancer et/ou des procédés permettant de retarder l'apparition du cancer par l'administration de nanoparticules comprenant de la rapamycine ou un dérivé de ce composé. Cette invention concerne aussi des compositions (par exemple des formes de dose unitaire) comprenant des nanoparticules, lesquelles comprennent une protéine porteuse et de la rapamycine ou un dérivé de ce composé. Cette invention concerne aussi des procédés de polythérapie pour le traitement du cancer qui consiste à administrer à un individu une quantité efficace de nanoparticules comprenant de la rapamycine ou un dérivé de ce composé et une seconde thérapie.
Desai Neil P.
Soon-Shiong Patrick
Trieu Vuong
Abraxis Bioscience Llc.
Smart & Biggar
LandOfFree
Nanoparticle comprising rapamycin and albumin as anticancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nanoparticle comprising rapamycin and albumin as anticancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanoparticle comprising rapamycin and albumin as anticancer... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2076335